Early-Infantile Developmental and Epileptic Encephalopathy (EIDEE): Research Report

Evidence cut-off: emphasis on literature published through 2024. Scope caution: EIDEE is an electroclinical syndrome/class, not one Mendelian disorder. Gene-numbered historical “EIEE” OMIM entries are separate gene-defined diseases and should not be conflated with the umbrella syndrome.

Executive summary

Early-infantile developmental and epileptic encephalopathy is a severe, etiologically heterogeneous epilepsy beginning at or before 3 months of age, accompanied by abnormal EEG activity and impaired development. Contemporary terminology subsumes much of the historical Ohtahara/early-infantile epileptic-encephalopathy spectrum, but not every infant with early seizures has EIDEE: acute provoked neonatal seizures, self-limited genetic neonatal epilepsy, vitamin-responsive epilepsy, structural epilepsy, and infection must be distinguished.

The strongest recent EIDEE-specific dataset is a 2023 prospective cohort of 80 children. Median seizure onset was 28 days; an etiology was established in 83%, comprising genetic 50%, structural 19%, vitamin-responsive metabolic 14%, and unknown 17%. Molecular diagnosis was obtained in 53/77 tested children (69%); 60% remained drug-resistant, 71% had severe developmental delay/intellectual disability, and 14% died during mean 30-month follow-up. These figures are referral-cohort estimates, not population prevalence. (agarwala2023earlyinfantiledevelopmentaland pages 4-6, agarwala2023earlyinfantiledevelopmentaland pages 1-3)

A database-ready synopsis is provided below.

Table: This table summarizes core disease-definition, cohort, mechanistic, diagnostic, therapeutic, and translational findings for Early-Infantile Developmental and Epileptic Encephalopathy. It is formatted for direct knowledge-base curation and flags ontology identifiers that require external registry verification.

1. Disease information

Definition and nomenclature

EIDEE denotes a developmental and epileptic encephalopathy with seizure onset by 3 months, developmental impairment attributable both to the underlying cause and potentially to epileptic activity, and a markedly abnormal EEG. Frequent seizures, including tonic, clonic, myoclonic, focal, and epileptic spasms, are typical. Burst suppression is characteristic but not obligatory; multifocal discharges or hypsarrhythmia may occur. (agarwala2023earlyinfantiledevelopmentaland pages 4-6, scheffer2024developmentalandepileptic pages 34-39)

Synonyms/related terms: early-infantile DEE; early infantile developmental and epileptic encephalopathy; neonatal-onset DEE; historical early infantile epileptic encephalopathy; Ohtahara syndrome; early myoclonic encephalopathy. The latter historical syndromes overlap the modern category but should remain searchable synonyms rather than exact equivalents in every record.

Identifiers: a single stable umbrella MONDO/OMIM/Orphanet identifier could not be verified from the retrieved primary literature. OMIM mainly represents gene-specific EIEE-numbered entities. ICD-10-CM generally codes the manifestations under epilepsy/epileptic encephalopathy rather than providing a sufficiently specific EIDEE code. ICD-11 and current MONDO entries should therefore be validated directly against the release used by the target knowledge base. MeSH indexing generally falls under Epileptic Encephalopathies.

The evidence summarized here is aggregated disease-level evidence from cohorts and reviews, not individual EHR data. Individual case/trial observations are identified as such.

2. Etiology, risk, and protective factors

EIDEE is a final common phenotype rather than a single genetic disease. In the 2023 cohort, causes were genetic in 50%, structural in 19%, vitamin-responsive metabolic in 14%, and unresolved in 17%. Relevant structural causes include malformations of cortical development and acquired neonatal injuries such as hypoxic–ischemic injury, stroke, infection, hypoglycemia, or trauma. (agarwala2023earlyinfantiledevelopmentaland pages 1-3, scheffer2024developmentalandepileptic pages 34-39)

Genetic risk

Major mechanistic groups include:

• Ion-channel disorders: SCN1A, SCN2A, SCN3A, SCN8A, SCN1B, KCNQ2, KCNB1, KCNT1, KCNA2, and calcium/receptor-channel genes.
• Synaptic-vesicle and synaptic-signaling disorders: STXBP1, DNM1, SNAP25, NECAP1, NBEA, and glutamate/GABA-receptor genes.
• Kinase/transcription/chromatin disorders: CDKL5, CSNK2B, ARX, FOXG1, CHD2 and related regulators.
• mTOR/cortical-malformation disorders: TSC1, TSC2, DEPDC5, NPRL2, NPRL3, MTOR and mosaic PI3K–AKT–mTOR-pathway variants.
• Transport/metabolic/mitochondrial disorders: SLC2A1, SLC6A1, ATP1A3, ALDH7A1, PNPO, BTD, POLG and mitochondrial genes.
• Ubiquitination/cellular-homeostasis disorders: biallelic UBA5 and WWOX, and dominant KLHL20. (specchio2024theexpandingfield pages 8-11, scheffer2024developmentalandepileptic pages 9-11, scheffer2024developmentalandepileptic pages 19-21, specchio2024theexpandingfield pages 1-6)

Variants may be missense, nonsense, frameshift, splice-altering, copy-number, structural, or mosaic. Most severe dominant channel/synaptic DEEs arise through germline de novo variants, whereas metabolic and several cellular-homeostasis disorders are autosomal recessive. X-linked disorders include CDKL5 and ARX. In the 2023 cohort, 67% of pathogenic findings followed dominant and 33% recessive inheritance. (agarwala2023earlyinfantiledevelopmentaland pages 4-6)

Allele frequency must be assessed per variant in gnomAD and ClinVar; pathogenic dominant EIDEE variants are ordinarily absent or exceptionally rare in population databases. ACMG classification and functional direction must be recorded separately. A VUS is not diagnostic without segregation, phenotype, and/or functional evidence.

Environmental, lifestyle, infectious, and protective factors

There is no established lifestyle exposure that causes the primary genetic syndrome, and no validated protective allele or diet that prevents it. Fever, infection, sleep deprivation, and metabolic stress can precipitate seizures in an affected child but are generally triggers, not causes. Prenatal/perinatal infection and hypoxic–ischemic injury are etiologic alternatives or structural causes. Inflammation may amplify channelopathy phenotypes in experimental systems, but a general human gene–environment model is not established. (specchio2024theexpandingfield pages 14-17)

3. Phenotypes and quality-of-life impact

The 80-child prospective cohort reported burst suppression in 42%, multifocal discharges in 30%, and hypsarrhythmia in 13%. Severe DD/ID affected 71% at follow-up. Relative to structural/vitamin-responsive cases, genetic/unknown cases had much higher odds of severe DD/ID (OR 57), autistic behavior (OR 37), tone abnormalities (OR 9), and movement disorder (OR 19). (agarwala2023earlyinfantiledevelopmentaland pages 4-6, agarwala2023earlyinfantiledevelopmentaland pages 1-3, agarwala2023earlyinfantiledevelopmentaland pages 8-10)

Suggested phenotype annotations include:

• early-infantile seizure onset; neonatal seizure; focal, tonic, clonic, myoclonic seizures; epileptic spasms;
• burst-suppression EEG, multifocal epileptiform discharges, hypsarrhythmia;
• global developmental delay (HP:0001263), intellectual disability (HP:0001249), developmental stagnation/regression;
• hypotonia, hypertonia/spasticity, dystonia, chorea, tremor, or other movement disorder;
• microcephaly, feeding/swallowing dysfunction, growth failure, cortical visual impairment;
• autistic behavior (HP:0000729 should be registry-checked), sleep disturbance, absent or limited speech.

The burden is typically profound: frequent seizures and rescue-medication use, impaired mobility and communication, feeding/respiratory complications, disrupted sleep, repeated hospitalizations, and lifelong caregiver dependence. Formal EIDEE-specific EQ-5D/SF-36 norms were not found; generic pediatric quality-of-life instruments may underrepresent profound neurodisability.

4. Genetic and molecular information

Functional interpretation is essential because the same gene can require opposite treatment depending on variant effect:

• SCN2A gain-of-function (GOF) variants typically produce neonatal/early-infantile focal epilepsy and may respond to phenytoin, carbamazepine, or lacosamide; loss-of-function (LOF) more often causes later developmental phenotypes and should not automatically be treated the same way.
• SCN8A GOF increases Nav1.6-mediated excitability and can cause infantile DEE; LOF is associated with different, often later phenotypes.
• SCN1A haploinsufficiency impairs firing of GABAergic inhibitory interneurons in Dravet syndrome; sodium-channel blockers may worsen this LOF disorder. Rare SCN1A GOF phenotypes require separate interpretation.
• KCNQ2 LOF reduces M-current, weakening neuronal repolarization and increasing excitability.
• KCNT1 GOF increases sodium-activated potassium-channel current and causes severe early epilepsy; quinidine is mechanistically plausible but clinical efficacy and tolerability are inconsistent.
• STXBP1 haploinsufficiency disrupts SNARE-mediated synaptic-vesicle release; it was the most frequent single-gene finding in the 2023 cohort (5 children).
• DEPDC5 loss disinhibits mTORC1; a somatic second hit can generate focal cortical dysplasia. (agarwala2023earlyinfantiledevelopmentaland pages 1-3, specchio2024theexpandingfield pages 27-29, specchio2024theexpandingfield pages 8-11, scheffer2024developmentalandepileptic pages 19-21)

No syndrome-wide epigenetic signature is established. Chromatin-regulator genes can cause DEE, and somatic mosaicism is important in cortical malformations. CNVs are clinically relevant: microarray detected diagnoses in 14% of the EIDEE cohort, although broader DEE reviews estimate approximately 4% in less selected populations. (agarwala2023earlyinfantiledevelopmentaland pages 1-3, scheffer2024developmentalandepileptic pages 11-13)

5. Mechanism and pathophysiology

A generalized causal chain is:

pathogenic variant/brain lesion/metabolic deficiency → altered neurodevelopment, synaptic release, receptor signaling, ion conductance, or energy metabolism → excitation–inhibition imbalance in immature cortical networks → recurrent seizures and epileptiform EEG activity → activity-dependent network injury layered upon the primary developmental defect → developmental stagnation/regression and neurological comorbidity.

Upstream mechanisms include altered cortical progenitor development, neuronal migration, channel biophysics, SNARE release, transcription/chromatin regulation, and mTOR signaling. Downstream mechanisms include network hypersynchrony, excitotoxic/oxidative stress, sleep disruption, neuroinflammation, and impaired activity-dependent circuit maturation. The relative contribution of the primary developmental defect versus seizures differs by genotype. (scheffer2024developmentalandepileptic pages 34-39, specchio2024theexpandingfield pages 6-8, specchio2024theexpandingfield pages 1-6)

Suggested annotations include GO:0042391 regulation of membrane potential, GO:0034220 ion transmembrane transport, GO:0007268 chemical synaptic transmission, GO:0016079 synaptic-vesicle exocytosis, GO:0031929 TOR signaling, and GO:0016567 protein ubiquitination. Relevant cells include glutamatergic neurons, GABAergic interneurons—especially parvalbumin-positive interneurons in selected sodium channelopathies—radial/apical neural progenitors, and glia. Relevant compartments include plasma membrane/axon initial segment, presynaptic active zone and synaptic vesicle, postsynaptic membrane, nucleus/chromatin, mitochondrion, and lysosome. (scheffer2024developmentalandepileptic pages 19-21, specchio2024theexpandingfield pages 6-8)

Disease-wide transcriptomic, proteomic, metabolomic, lipidomic, single-cell, and spatial signatures are not sufficiently replicated for clinical annotation. Such findings are mainly gene-specific and preclinical.

6. Anatomy

The primary organ is the central nervous system, especially bilateral cerebral cortex and distributed thalamocortical networks. Structural subgroups may involve focal cortex, hippocampus, basal ganglia, cerebellum, or diffuse malformations. Suggested terms include UBERON:0000955 brain and UBERON:0000956 cerebral cortex. There is generally no fixed lateralization unless a focal malformation or stroke is causal. Secondary involvement includes musculoskeletal contractures from immobility/spasticity, aspiration-related respiratory disease, gastrointestinal feeding problems, impaired growth, and sleep/autonomic dysfunction.

7. Temporal development and natural history

Onset is neonatal or within the first three postnatal months and may be abrupt, with clusters, status epilepticus, or rapidly increasing seizure burden. In the 2023 cohort, 32.5% began within 7 days and median onset was 28 days. Evolution to infantile epileptic spasms syndrome or later multifocal/Lennox–Gastaut-like epilepsy may occur. The course is chronic and often drug-resistant rather than classically relapsing–remitting. Seizure remission does not guarantee developmental recovery because the genetic/structural disorder has independent developmental effects. (agarwala2023earlyinfantiledevelopmentaland pages 4-6)

Early infancy is the critical diagnostic and therapeutic period: treatable metabolic disease, resectable structural lesions, and mechanism-specific channel therapy should be identified before prolonged status epilepticus and disrupted circuit maturation.

8. Epidemiology, inheritance, and population

Robust population incidence or prevalence for the umbrella EIDEE syndrome is unavailable. A tertiary-center cohort cannot supply population prevalence. Syndrome-specific Scottish estimates cited in a 2024 review include CDKL5-DEE incidence of 2.36 per 100,000 live births and PCDH19 clustering epilepsy of 4.85 per 100,000, but these are not EIDEE-wide estimates. (scheffer2024developmentalandepileptic pages 34-39)

Both sexes are affected; sex ratios vary by gene. The 2023 cohort had a male:female ratio of 1.5:1, but this should not be generalized globally. X-linked disorders create gene-specific sex effects. No consistent ethnic/geographic predisposition is established; ascertainment and access to sequencing strongly affect reported distributions. (agarwala2023earlyinfantiledevelopmentaland pages 4-6)

Penetrance is often high for severe de novo variants but is gene/variant-specific. Expressivity is variable. Anticipation is not a general feature. Parental mosaicism was reported in approximately 8% of apparently de novo DEE cases when sensitive methods were used; recurrence risk can therefore exceed the conventional ~1% germline-mosaicism estimate. Recessive disease risk rises with consanguinity, and founder variants may be population-specific. (scheffer2024developmentalandepileptic pages 13-15)

9. Diagnosis

Recommended workflow

1. Stabilize and document seizures: continuous or prolonged video-EEG is essential because neonatal seizures may be electrographic-only. Characterize background, burst suppression, multifocal activity, and spasms.
2. Identify acquired causes urgently: glucose, electrolytes, calcium/magnesium, blood gas, CBC/cultures, infection testing, and assessment for hypoxic–ischemic injury, hemorrhage, stroke, or trauma.
3. MRI: 3-T epilepsy-protocol MRI, including diffusion and susceptibility sequences, to identify malformation, ischemia, hemorrhage, or focal cortical dysplasia. (scheffer2024developmentalandepileptic pages 11-13)
4. Treatable metabolic testing: ammonia, lactate/pyruvate, plasma amino acids, acylcarnitines, urine organic acids, biotinidase, and targeted CSF glucose, lactate, amino acids, and neurotransmitters when indicated. Prioritize ALDH7A1, PNPO, BTD, SLC2A1, mitochondrial and POLG-related disease. (scheffer2024developmentalandepileptic pages 13-15)
5. Do not delay monitored vitamin trials when appropriate: pyridoxine, pyridoxal-5′-phosphate, folinic acid, and biotin, with cardiorespiratory/EEG monitoring because pyridoxine can cause apnea. In the cohort, metabolic testing diagnosed biotinidase deficiency in 3/41 tested children, and all metabolic etiologies were vitamin-responsive. (agarwala2023earlyinfantiledevelopmentaland pages 1-3)
6. Rapid trio exome or genome sequencing: increasingly favored early because of high heterogeneity and time-sensitive treatment. Rapid genome sequencing in infants under one year with seizures found an etiology in 46% at median 37 days; overall NGS identifies about half of DEE. (scheffer2024developmentalandepileptic pages 9-11)
7. CNV and mosaic analysis: ensure exon-level CNV calling; use CMA if not captured or when dysmorphism/malformation suggests CNV. Consider deep sequencing, affected-tissue sequencing, or droplet-digital PCR for low-level mosaicism. (scheffer2024developmentalandepileptic pages 11-13)
8. Reanalysis: periodically reanalyze negative exome/genome data; consider mtDNA, repeat expansion, RNA sequencing, methylation signatures, or functional assays when phenotype directs. Karyotype/FISH is not first-line unless a cytogenetic rearrangement is suspected.

The prospective study’s exact abstract statement was: “A molecular diagnosis was achieved in 53 out of 77 patients tested (69%). Next-generation sequencing had a yield of 51%, while microarray had a yield of 14%.” (Publication: 14 September 2023; DOI URL: https://doi.org/10.1093/braincomms/fcad243.) (agarwala2023earlyinfantiledevelopmentaland pages 1-3)

Differential diagnosis

Exclude acute symptomatic neonatal seizures, self-limited familial neonatal/infantile epilepsy, infantile epileptic spasms syndrome, epilepsy of infancy with migrating focal seizures, Dravet syndrome, glycine encephalopathy, pyridoxine/PNPO/folinic-acid-responsive epilepsy, biotinidase deficiency, GLUT1 deficiency, mitochondrial disease, congenital infection, autoimmune encephalitis, hypoxic–ischemic injury, stroke, and structural malformation. EEG pattern alone is not etiologic.

10. Outcomes and prognosis

In the 2023 prospective cohort, 60% remained drug-resistant, 71% had severe DD/ID, and 14% died over mean 30 months. Median time to seizure control was 3 days for vitamin-responsive disease versus 75 days structural, 80 days unknown, and 90 days genetic. Vitamin responsiveness was the only independently significant favorable seizure-control factor (P=0.02). (agarwala2023earlyinfantiledevelopmentaland pages 4-6, agarwala2023earlyinfantiledevelopmentaland pages 8-10)

Mortality mechanisms include status epilepticus, respiratory/aspiration complications, infection, underlying metabolic disease, and sudden unexpected death in epilepsy. There are no reliable syndrome-wide 5- or 10-year survival estimates. Favorable prognostic factors include an immediately treatable metabolic deficiency, a completely resectable lesion, and early mechanism-matched treatment. Severe neonatal EEG background abnormality, persistent status, profound early developmental impairment, and drug resistance generally indicate poorer outcomes.

11. Treatment and real-world implementation

Acute and conventional treatment

Treat status epilepticus according to neonatal/pediatric protocols while pursuing etiology. Phenobarbital, levetiracetam, benzodiazepines, phenytoin/fosphenytoin, and other ASMs are selected according to seizure type, age, organ function, and suspected mechanism. No single ASM treats all EIDEE.

Genotype/etiology-guided treatment

• Vitamin-dependent epilepsy: pyridoxine for ALDH7A1; pyridoxal-5′-phosphate for PNPO; folinic acid in selected responsive disorders; biotin for biotinidase deficiency.
• SCN2A/SCN8A GOF and some KCNQ2 early-onset disease: sodium-channel blockers may be unusually effective. Six genotype-guided responders in the 2023 cohort carried SCN1A, KCNQ2, FGF12, SCN8A, or SCN2A findings. (agarwala2023earlyinfantiledevelopmentaland pages 8-10, specchio2024theexpandingfield pages 8-11)
• SCN1A-LOF/Dravet: avoid maintenance carbamazepine and oxcarbazepine because seizure aggravation can occur; use syndrome-supported regimens such as valproate, clobazam, stiripentol, cannabidiol, and fenfluramine as clinically appropriate. (scheffer2024developmentalandepileptic pages 9-11)
• KCNT1 GOF: quinidine is experimental/off-label; one cohort child benefited, but ECG/QT and drug-interaction monitoring is mandatory and responses are variable. (agarwala2023earlyinfantiledevelopmentaland pages 8-10, specchio2024theexpandingfield pages 8-11)
• mTORopathy: everolimus has established evidence for tuberous-sclerosis-complex-associated seizures, not for EIDEE indiscriminately.
• GLUT1 deficiency: ketogenic diet is disease-targeted therapy.

The ketogenic diet is also used for drug-resistant EIDEE. A 2024 study reported approximately 30% seizure freedom and 60% achieving >50% seizure reduction in the relevant young-patient context, but these uncontrolled results should not be interpreted as a universal EIDEE response rate. (nguyen2024genotypedriventherapeuticsin pages 9-10)

For a unifocal, resectable lesion, early epilepsy-surgery assessment can be transformative. Palliative options for persistent generalized/multifocal disease include vagus-nerve stimulation, corpus callosotomy, and other neuromodulation, although EIDEE-specific comparative evidence is limited. (scheffer2024developmentalandepileptic pages 11-13)

Supportive care requires feeding/swallow assessment, nutrition and gastrostomy when needed, respiratory and sleep management, physiotherapy, occupational/speech/communication therapy, management of tone and movement disorders, vision/hearing services, rescue plans, SUDEP counseling, psychosocial support, and palliative-care involvement where appropriate. Suggested NCIT mappings include Anticonvulsant Therapy, Ketogenic Diet Therapy, Epilepsy Surgery, Vagus Nerve Stimulation, Physical Therapy, Occupational Therapy, Speech Therapy, Genetic Counseling, Antisense Oligonucleotide Therapy, and Gene Therapy; local NCIT concept codes should be release-verified.

12. 2023–2024 research developments and trials

The major conceptual advance is movement from gene-name prescribing toward variant-mechanism prescribing. The 2024 Lancet review emphasizes that GOF should generally be reduced, whereas LOF/haploinsufficiency may require transcript or gene augmentation. (specchio2024theexpandingfield pages 8-11, specchio2024theexpandingfield pages 6-8)

Emerging approaches include ASOs, AAV gene replacement, CRISPR activation, and stop-codon read-through. In mouse Dravet models, AAV-mediated SCN1A augmentation and dCas9/CRISPRa activation improved seizures and survival; cell-selective targeting of inhibitory neurons is particularly relevant. Patient-derived iPSC neurons demonstrate impaired inhibitory-neuron excitability in SCN1A disease. These are preclinical findings and do not establish routine efficacy. (specchio2024theexpandingfield pages 27-29, scheffer2024developmentalandepileptic pages 19-21, specchio2024theexpandingfield pages 14-17, scheffer2024developmentalandepileptic pages 17-19)

Retrieved ClinicalTrials.gov records included:

• NCT05737784: PRAX-222/elsunersen-like SCN2A-lowering ASO program for early-onset SCN2A-DEE; phase 1/2, 60 planned, recruiting in the retrieved record.
• NCT07019922: elsunersen in pediatric SCN2A-DEE; phase 3, 40 planned, recruiting.
• NCT04639310/NCT04912856: XEN496 (ezogabine) and extension in KCNQ2-DEE; both terminated, enrollment 8.
• NCT04937062: phenylbutyrate for monogenic DEE; early phase 1, 50 planned, active-not-recruiting.
• NCT04873869/NCT05226780: NBI-921352 for SCN8A-DEE and extension; terminated, enrollment 8.
• NCT06983158: CAP-002 gene therapy for STXBP1 encephalopathy; phase 1/2, terminated after enrollment of 1 in the retrieved record.

Trial statuses are dynamic and must be rechecked at https://clinicaltrials.gov before curation or clinical use.

13. Prevention

There is no vaccine, lifestyle modification, or population-screening program that prevents sporadic de novo EIDEE. Primary prevention is therefore reproductive rather than behavioral: molecular diagnosis, parental high-depth testing, counseling about gonadal/somatic mosaicism, preimplantation genetic testing, chorionic-villus sampling, or amniocentesis. (scheffer2024developmentalandepileptic pages 13-15)

Secondary prevention consists of rapid recognition, EEG confirmation, early genomic diagnosis, and immediate treatment of vitamin-responsive/metabolic disease or a resectable lesion. Tertiary prevention includes seizure-rescue plans, aspiration and infection prevention, nutrition, contracture prevention, bone health, SUDEP counseling, and rehabilitation. Cascade/carrier testing applies to inherited dominant, recessive, X-linked, or mitochondrial diagnoses; universal newborn screening for EIDEE is not currently established.

14. Other species and natural disease

No unitary, naturally occurring veterinary syndrome equivalent to human EIDEE was established in the retrieved evidence. Orthologous channel, synaptic, and metabolic diseases occur in animals, but annotation should be made at the gene-specific level through OMIA rather than assigning the entire human umbrella syndrome. The condition is not infectious or zoonotic and has no cross-species transmission.

15. Model organisms

• Mouse (NCBITaxon:10090): heterozygous/conditional Scn1a models reproduce spontaneous seizures, temperature sensitivity, premature death, and inhibitory-interneuron dysfunction; Scn2a, Scn8a, Kcnq2, Stxbp1, and Cdkl5 models capture selected seizure/developmental phenotypes. Genetic background strongly changes severity.
• Zebrafish (NCBITaxon:7955): scalable seizure and drug-screening models exist for several channel/synaptic genes, but brain development and pharmacokinetics limit direct translation.
• Drosophila/C. elegans: useful for conserved ion-channel and synaptic pathways, with limited representation of mammalian cortical circuitry.
• Patient iPSC-derived neurons and cerebral organoids: enable variant-specific electrophysiology, GOF/LOF assignment, rescue experiments, and study of human progenitor/circuit phenotypes. Limitations include cellular immaturity, line-to-line variation, and absence of whole-organism pharmacology. In SCN1A iPSC systems, inhibitory neurons show selective functional impairment. (scheffer2024developmentalandepileptic pages 19-21)

The best-supported applications are mechanism validation, functional classification of VUS, drug screening, therapeutic-window studies, and testing ASO/AAV/CRISPR strategies. Experimental rescue in a model does not itself prove clinical efficacy.

Evidence limitations and authoritative interpretation

The 2024 Nature Reviews Disease Primers and Lancet Child & Adolescent Health reviews support rapid molecular diagnosis and mechanism-stratified therapy, while emphasizing that DEEs encompass hundreds of genes and that developmental morbidity often persists despite seizure improvement. (scheffer2024developmentalandepileptic pages 34-39, specchio2024theexpandingfield pages 8-11, specchio2024theexpandingfield pages 1-6, scheffer2024developmentalandepileptic pages 9-11)

The most directly applicable abstract conclusion from the 2023 prospective study is: “Genetic aetiologies are the most common cause of early-infantile developmental and epileptic encephalopathies… Patients with vitamin responsive epilepsies had the best probability of seizure control.” (Published September 2023; https://doi.org/10.1093/braincomms/fcad243.) (agarwala2023earlyinfantiledevelopmentaland pages 1-3)

Major limitations are small rare-disease cohorts, tertiary-center referral bias, changing terminology, pooling of mechanistically different disorders, sparse long-term adult data, and predominantly observational evidence for precision treatments. Exact OMIM, MONDO, Orphanet, HPO, NCIT, HGNC, and ClinVar identifiers should be validated against current database releases before production ingestion.

References

1. (agarwala2023earlyinfantiledevelopmentaland pages 4-6): Pooja Agarwala, Bhuvandeep Narang, Thenral S. Geetha, Nilesh Kurwale, Praveena L Samson, Tamanna Golani, Udita Mahadevia, Ramprasad Vedam, Sakthivel Murugan, Sagnik Chatterjee, Pradeep Goyal, and Vivek Jain. Early-infantile developmental and epileptic encephalopathy: the aetiologies, phenotypic differences and outcomes—a prospective observational study. Brain Communications, Sep 2023. URL: https://doi.org/10.1093/braincomms/fcad243, doi:10.1093/braincomms/fcad243. This article has 17 citations and is from a peer-reviewed journal.

2. (agarwala2023earlyinfantiledevelopmentaland pages 1-3): Pooja Agarwala, Bhuvandeep Narang, Thenral S. Geetha, Nilesh Kurwale, Praveena L Samson, Tamanna Golani, Udita Mahadevia, Ramprasad Vedam, Sakthivel Murugan, Sagnik Chatterjee, Pradeep Goyal, and Vivek Jain. Early-infantile developmental and epileptic encephalopathy: the aetiologies, phenotypic differences and outcomes—a prospective observational study. Brain Communications, Sep 2023. URL: https://doi.org/10.1093/braincomms/fcad243, doi:10.1093/braincomms/fcad243. This article has 17 citations and is from a peer-reviewed journal.

3. (scheffer2024developmentalandepileptic pages 34-39): Ingrid E. Scheffer, Sameer Zuberi, Heather C. Mefford, Renzo Guerrini, and Amy McTague. Developmental and epileptic encephalopathies. Nature reviews. Disease primers, 10 1:61, Sep 2024. URL: https://doi.org/10.1038/s41572-024-00546-6, doi:10.1038/s41572-024-00546-6. This article has 157 citations.

4. (agarwala2023earlyinfantiledevelopmentaland pages 8-10): Pooja Agarwala, Bhuvandeep Narang, Thenral S. Geetha, Nilesh Kurwale, Praveena L Samson, Tamanna Golani, Udita Mahadevia, Ramprasad Vedam, Sakthivel Murugan, Sagnik Chatterjee, Pradeep Goyal, and Vivek Jain. Early-infantile developmental and epileptic encephalopathy: the aetiologies, phenotypic differences and outcomes—a prospective observational study. Brain Communications, Sep 2023. URL: https://doi.org/10.1093/braincomms/fcad243, doi:10.1093/braincomms/fcad243. This article has 17 citations and is from a peer-reviewed journal.

5. (scheffer2024developmentalandepileptic pages 9-11): Ingrid E. Scheffer, Sameer Zuberi, Heather C. Mefford, Renzo Guerrini, and Amy McTague. Developmental and epileptic encephalopathies. Nature reviews. Disease primers, 10 1:61, Sep 2024. URL: https://doi.org/10.1038/s41572-024-00546-6, doi:10.1038/s41572-024-00546-6. This article has 157 citations.

6. (scheffer2024developmentalandepileptic pages 19-21): Ingrid E. Scheffer, Sameer Zuberi, Heather C. Mefford, Renzo Guerrini, and Amy McTague. Developmental and epileptic encephalopathies. Nature reviews. Disease primers, 10 1:61, Sep 2024. URL: https://doi.org/10.1038/s41572-024-00546-6, doi:10.1038/s41572-024-00546-6. This article has 157 citations.

7. (specchio2024theexpandingfield pages 8-11): Nicola Specchio, Marina Trivisano, Eleonora Aronica, Simona Balestrini, Alexis Arzimanoglou, Gaia Colasante, J Helen Cross, Sergiusz Jozwiak, Jo M Wilmshurst, Federico Vigevano, Stéphane Auvin, Rima Nabbout, and Paolo Curatolo. The expanding field of genetic developmental and epileptic encephalopathies: current understanding and future perspectives. The Lancet. Child & adolescent health, 8 11:821-834, Nov 2024. URL: https://doi.org/10.1016/s2352-4642(24)00196-2, doi:10.1016/s2352-4642(24)00196-2. This article has 35 citations.

8. (specchio2024theexpandingfield pages 6-8): Nicola Specchio, Marina Trivisano, Eleonora Aronica, Simona Balestrini, Alexis Arzimanoglou, Gaia Colasante, J Helen Cross, Sergiusz Jozwiak, Jo M Wilmshurst, Federico Vigevano, Stéphane Auvin, Rima Nabbout, and Paolo Curatolo. The expanding field of genetic developmental and epileptic encephalopathies: current understanding and future perspectives. The Lancet. Child & adolescent health, 8 11:821-834, Nov 2024. URL: https://doi.org/10.1016/s2352-4642(24)00196-2, doi:10.1016/s2352-4642(24)00196-2. This article has 35 citations.

9. (scheffer2024developmentalandepileptic pages 11-13): Ingrid E. Scheffer, Sameer Zuberi, Heather C. Mefford, Renzo Guerrini, and Amy McTague. Developmental and epileptic encephalopathies. Nature reviews. Disease primers, 10 1:61, Sep 2024. URL: https://doi.org/10.1038/s41572-024-00546-6, doi:10.1038/s41572-024-00546-6. This article has 157 citations.

10. (scheffer2024developmentalandepileptic pages 13-15): Ingrid E. Scheffer, Sameer Zuberi, Heather C. Mefford, Renzo Guerrini, and Amy McTague. Developmental and epileptic encephalopathies. Nature reviews. Disease primers, 10 1:61, Sep 2024. URL: https://doi.org/10.1038/s41572-024-00546-6, doi:10.1038/s41572-024-00546-6. This article has 157 citations.

11. (nguyen2024genotypedriventherapeuticsin pages 9-10): Yen Thi My Nguyen, Bao-Quoc Vu, Duy-Khai Nguyen, Ngoc-Vinh Quach, Liem Thanh Bui, Jeonghan Hong, and Chi-Bao Bui. Genotype-driven therapeutics in dee and metabolic epilepsy: navigating treatment efficacy and drug resistance. Scientific Reports, Sep 2024. URL: https://doi.org/10.1038/s41598-024-72683-7, doi:10.1038/s41598-024-72683-7. This article has 5 citations and is from a peer-reviewed journal.

12. (scheffer2024developmentalandepileptic pages 17-19): Ingrid E. Scheffer, Sameer Zuberi, Heather C. Mefford, Renzo Guerrini, and Amy McTague. Developmental and epileptic encephalopathies. Nature reviews. Disease primers, 10 1:61, Sep 2024. URL: https://doi.org/10.1038/s41572-024-00546-6, doi:10.1038/s41572-024-00546-6. This article has 157 citations.

13. (specchio2024theexpandingfield pages 27-29): Nicola Specchio, Marina Trivisano, Eleonora Aronica, Simona Balestrini, Alexis Arzimanoglou, Gaia Colasante, J Helen Cross, Sergiusz Jozwiak, Jo M Wilmshurst, Federico Vigevano, Stéphane Auvin, Rima Nabbout, and Paolo Curatolo. The expanding field of genetic developmental and epileptic encephalopathies: current understanding and future perspectives. The Lancet. Child & adolescent health, 8 11:821-834, Nov 2024. URL: https://doi.org/10.1016/s2352-4642(24)00196-2, doi:10.1016/s2352-4642(24)00196-2. This article has 35 citations.

14. (specchio2024theexpandingfield pages 14-17): Nicola Specchio, Marina Trivisano, Eleonora Aronica, Simona Balestrini, Alexis Arzimanoglou, Gaia Colasante, J Helen Cross, Sergiusz Jozwiak, Jo M Wilmshurst, Federico Vigevano, Stéphane Auvin, Rima Nabbout, and Paolo Curatolo. The expanding field of genetic developmental and epileptic encephalopathies: current understanding and future perspectives. The Lancet. Child & adolescent health, 8 11:821-834, Nov 2024. URL: https://doi.org/10.1016/s2352-4642(24)00196-2, doi:10.1016/s2352-4642(24)00196-2. This article has 35 citations.

15. (specchio2024theexpandingfield pages 1-6): Nicola Specchio, Marina Trivisano, Eleonora Aronica, Simona Balestrini, Alexis Arzimanoglou, Gaia Colasante, J Helen Cross, Sergiusz Jozwiak, Jo M Wilmshurst, Federico Vigevano, Stéphane Auvin, Rima Nabbout, and Paolo Curatolo. The expanding field of genetic developmental and epileptic encephalopathies: current understanding and future perspectives. The Lancet. Child & adolescent health, 8 11:821-834, Nov 2024. URL: https://doi.org/10.1016/s2352-4642(24)00196-2, doi:10.1016/s2352-4642(24)00196-2. This article has 35 citations.

Artifacts

• Edison artifact artifact-00